Jan 22 (Reuters) - Corcept Therapeutics said on Thursday a late-stage trial showed its experimental drug in combination with chemotherapy helped reduce the risk of death in patients with a type of ...

Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities ...

Investigators compared the efficacy and safety of suvemcitug plus chemotherapy vs chemotherapy plus placebo for patients with platinum-refractory or resistant ovarian cancer.

Women with certain genetic mutations are at extremely high risk of ovarian cancer. Now, some researchers are trying a new ...

Eli Lilly has won U.S. Food and Drug Administration breakthrough -therapy designation for its sofetabart mipitecan drug candidate for certain patients with ovarian cancer.

Ovarian cancer is a highly lethal gynecological malignancy with limited therapeutic options for recurrent and drug-resistant ...

In 2022, more than 13,000 people died from ovarian cancer, according to the CDC. A common blood test for ovarian cancer is more likely to fall short for Black and Native American women, according to a ...

A special first birthday celebration was held at the Daegu Cha Hospital Infertility Center on the 20th. The protagonists were ...

A systematic review found that bilateral salpingectomy is associated with roughly an 80% reduction in risk for the serous ...